Effect of Sacubitril/Valsartan on Natriuretic Peptide in Patients with Compensated Heart Failure

Effect of Sacubitril/Valsartan on Natriuretic Peptide in Patients with Compensated Heart Failure - Sacubitril/Valsartan in Compensated HF

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046574

Enrollment

Registered

2022-01-08

Start date

2021-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

Treatment of Sacubitril/Valsartan Treatment of ACE-I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Compensated HF patients visiting the outpatient clinics who were administrated angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)

Exclusion criteria

Exclusion criteria: Patients with end-stage chronic kidney disease (eGFR<30 mL/min/1.73m2) were excluded from present study

Design outcomes

Primary

Measure	Time frame
natriuretic peptide families	—

Secondary

Measure	Time frame
1) Serum Renin, aldosterone and AngiotensinII 2) medication 3) age, gender, presence of de novo or recurrent HF, etiology of HF, past medical history (risk factors for atherosclerosis [diabetes mellitus, hypertension, and dyslipidemia], and chronic kidney disease), vital signs (systolic blood pressure [SBP] and heart rate), laboratory data (blood urea nitrogen, creatinine, total bilirubin, sodium, potassium, hemoglobin and C-reactive protein [CRP]) 4) left ventricular ejection fraction (LVEF) on echocardiography 5) Prognosis (mortality and heart failure event within 1 year)	—

Measure

Time frame

1) Serum Renin, aldosterone and AngiotensinII 2) medication 3) age, gender, presence of de novo or recurrent HF, etiology of HF, past medical history (risk factors for atherosclerosis [diabetes mellitus, hypertension, and dyslipidemia], and chronic kidney disease), vital signs (systolic blood pressure [SBP] and heart rate), laboratory data (blood urea nitrogen, creatinine, total bilirubin, sodium, potassium, hemoglobin and C-reactive protein [CRP]) 4) left ventricular ejection fraction (LVEF) on echocardiography 5) Prognosis (mortality and heart failure event within 1 year)

—

Countries

Japan

Contacts

Public ContactAkihiro Shirakabe

Nippon Medical School Chiba Hokusoh Hospital Division of Intensive Care Unit

s6042@nms.ac.jp0476991111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026